| Summary: | The NICE surveillance programme reviewed the guideline on Long-acting reversible contraception (NICE clinical guideline 30) in 2011, and found changes to product licensing that affected the section of the guideline on progestogen-only subdermal implants. The full report can be found here: http://www.nice.org.uk/CG30/ New recommendations relating to progestogen-only subdermal implants have been made in this addendum. You are invited to comment on these new recommendations. Some recommendations can be made with more certainty than others. The wording used in the recommendations in this addendum denotes the certainty with which the recommendation is made (the strength of the recommendation). For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also 'Patient-centred care')
|
|---|